Global Recombinant Technology Market – Industry Trends and Forecast to 2029

Análise e dimensão do mercado de tecnologia recombinante

A tecnologia recombinante está a ser rapidamente utilizada para tratar muitas doenças, nomeadamente através da criação de novos produtos farmacêuticos e vacinas. Este é um dos principais impulsionadores do mercado, juntamente com o avanço dos métodos de tratamento provocado pelo desenvolvimento de ferramentas de diagnóstico, sistemas de monitorização e novas modalidades terapêuticas, entre outros. Além disso, o mercado da tecnologia recombinante está a ser impulsionado pelo aumento da investigação sobre organismos geneticamente modificados (OGM), que incluem microrganismos considerados biodegradadores e produtores de combustível limpo.

A Data Bridge Market Research analisa que o mercado de tecnologia recombinante, que foi de 690,4 mil milhões de dólares em 2021, subiria para 1.127,25 mil milhões de dólares até 2029, e deverá passar por um CAGR de 6,32% durante o período de previsão de 2022 a 2029. Além dos insights de mercado, tais como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes do mercado e o cenário de mercado, o relatório de mercado com curadoria da equipa de estudos de mercado da O Data Bridge inclui também análise especializada aprofundada, epidemiologia do paciente, análise de pipeline, análise de preços e quadro regulamentar.

Âmbito e segmentação do mercado de tecnologia recombinante      

Definição de mercado

A tecnologia recombinante é também conhecida como engenharia genética. Atualmente é utilizado com frequência para modificar material genético fora de um organismo para produzir características melhores e desejáveis ​​​​em seres vivos. Envolve a inserção de fragmentos de ADN de várias fontes que possuem a sequência genética desejada num vetor adequado. Além disso, ajuda na produção segura, económica e suficiente de proteínas essenciais necessárias à nutrição e ao combate a problemas de saúde. Como resultado, tem aplicações em vários campos e um grande potencial para melhorar os recursos alimentares, melhorar a saúde e aumentar a resiliência a vários efeitos ambientais negativos.

Dinâmica do mercado da tecnologia recombinante

Motoristas

• Crescente indústria biofarmacêutica

Espera-se que o mercado da tecnologia recombinante cresça a um ritmo mais rápido durante o período de previsão 2022 e 2029 devido a fatores que incluem a indústria biofarmacêutica em expansão, um aumento do avanço tecnológico na área, um aumento da consciência da saúde humana e animal, e um aumento da taxa de sucesso da insulina recombinante. Por outro lado, o financiamento governamental para a tecnologia recombinante na terapia genética , diagnóstico clínico e produção farmacêutica criará uma riqueza de perspetivas de crescimento para o mercado da tecnologia recombinante durante o período de previsão.

• Aumento da prevalência de doenças infeciosas

O aumento dos produtos de alta tecnologia, a expansão das aprovações regulamentares, a elevada prevalência de doenças infeciosas e o aumento da penetração no mercado das grandes empresas contribuem para o aumento da necessidade de vacinas recombinantes a nível mundial. O mercado está em expansão devido à melhoria da sensibilização para os cuidados de saúde, políticas de reembolso atrativas, investigação e inovação no desenvolvimento de medicamentos e vacinas, aumento do rendimento médio individual e muito mais.

Oportunidades

Estudos de investigação em curso alimentam o crescimento do mercado para explorar o potencial da planta como sistema de expressão que deverá impulsionar a adoção de sistemas de expressão de planos para o desenvolvimento de produtos GM nos próximos anos. Isto proporcionará oportunidades benéficas para o crescimento do mercado.

Além disso, um aumento no número de mercados emergentes e lançamentos de novos produtos proporcionará ainda mais oportunidades benéficas para o crescimento do mercado de tecnologia recombinante durante o período de previsão.

Restrições/Desafios

On the other hand, the scientific, regulatory and ethical challenges along with rising risk in using the genetically modified food will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the recombinant technology market.

• High vaccine costs and side effects of treatment

Market growth is likely to be impeded by factors such as high vaccine costs, risks associated with live attenuated vaccines, as well as sore throat irritability after vaccine administration, and strict regulatory policies. 

This recombinant technology market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the recombinant technology market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Recombinant Technology Market

The global pandemic COVID-19 has caused stress across many businesses and industry verticals, not just for human lives. Several million people around the world have contracted the COVID-19 disease, and with more cases becoming active every day, it is still difficult to forecast how long the pandemic will last. The COVID-19 outbreak has had a significant impact on recombinant technology. However, because vaccines are so effective at preventing fatal illnesses, their business has been expanding globally. The prognosis for the year predicts that increased R&D will result in the potential development of a COVID-19 recombinant vaccine.

Recent Development

• In February 2022, the European Medicines Agency's Committee for the Use of Medicinal Products provided VBI Vaccines Inc. with favorable feedback. This viewpoint was in reference to the PreHevbri 3-antigen hepatitis B (HBV) vaccine, developed to provide adults with immunity against hepatitis B virus infection. Because hepatitis B is still a concern for public health in Europe, this favourable judgment gave medical professionals a useful tool for preventing patients from contracting the illness.
• In June 2021, the world's top provider of life science research tools and services, GenScript USA Inc., debuted the GenWandTM Double-Stranded DNA (dsDNA) Service for manufacturing CRISPR knock-in homology-directed repair (HDR) templates in T cell engineering.
• In March 2022, PreHevbrio (Recombinant Hepatitis B Vaccine) was made available to individuals over the age of 18 in the United States by VBI Vaccines Inc. to prevent infection by any known subtype of the hepatitis B virus (HBV). Additionally, the release of the vaccine will increase immunization rates with the help of US healthcare experts and will protect patients, especially adult patients, against HBV.

Global Recombinant Technology Market Scope

The recombinant technology market is segmented on the basis of product, component, application and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Medical
• Therapeutic Agent
• Human Protein
• Vaccines
• Non-Medical
• Biotech Crops
• Specialty Chemicals
• Others

 Component

• Expression System
• Cloning Vector

Application

• Food and Agriculture
• Health and Disease
• Environment
• Others

 End Use

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Diagnostic Laboratories

Recombinant Technology Market Regional Analysis/Insights

The recombinant technology market is analysed and market size insights and trends are provided by country, product, component, application and end use as referenced above.

The countries covered in the recombinant technology market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the recombinant technology market due to the prevalence of various biopharmaceutical companies along with the high adoption of advanced technology.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the prevalence of low-cost manufacturing centres.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The recombinant technology market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for recombinant technology market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Global recombinant technology market. The data is available for historic period 2010-2020.

Competitive Landscape and Recombinant Technology Market Share Analysis

The recombinant technology market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to recombinant technology market.

Some of the major players operating in the recombinant technology market are:

• Amgen Inc (U.S.)
• Novartis AG (Germany)
• Novo Nordisk A/S (Denmark)
• Sanofi (France)
• Merck & Co., Inc. (U.S.)
• Genentech, Inc. (U.S.)
• GenScript (U.S.)
• Pfizer Inc. (U.S.)
• Biocon (India)
• GlaxoSmithKline plc. (U.K.)
• New England Biolabs (U.K.) Ltd. (U.K.)
• Cibus (U.S.)
• Horizon Discovery Ltd. (U.K.)
• Boehringer Ingelheim International GmbH (Germany)
• Thermo Fisher Scientific Inc. (U.S.)

SKU-54478